Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry
Annals of Clinical and Translational Neurology · 2026
DOI: 10.1002/acn3.70356 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Marika Pane und 43 weiteren Autor:innen. Beteiligte Einrichtung: Nemo Clinical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Genetic Therapy, Outcome Assessment, Health Care. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen, Novartis, Roche Italia.
Abstract (Originalsprache)
Objective
Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited. The aim of this 24‐month prospective observational study is to comprehensively describe the clinical outcomes of an Italian cohort of SMA I patients treated with OA.
Methods
Based on recent literature, patients' treatment status was categorized as: monotherapy (OA only), bridge therapy (transition to OA within 3 months of starting nusinersen or risdiplam), or switch therapy (transition to OA after > 3 months of 1st treatment). Linear mixed‐effects models examined predictors of improvement (CHOP‐INTEND), adjusting for baseline motor function, SMN2 copy number, age, and prior treatment. Descriptive analyses were used to show changes in motor, respiratory, and nutritional milestones.
Results
The cohort included 64 patients: 27 monotherapy, 9 bridge, and 28 switch. All patients showed significant improvement over 24 months ( β = 20.40 points/year, p < 0.001). Patients who switched showed slower improvement ( β = −3.76, p = 0.038) compared to monotherapy, while those who bridged showed no difference. Older age at treatment was associated with slower improvement ( β = −1.48 points/year per month, p = 0.002). Of 49 non‐sitters at baseline, 39 (80%) achieved sitting and 5 (10%) achieved walking. No new safety signals emerged in the second year of follow‐up.
Interpretation
Age and baseline motor functional status significantly influence outcomes; however, substantial confounding, particularly the initial treatment, limits the ability to isolate individual effects. Longer follow‐up is essential for evaluating therapeutic responses in heterogeneous SMA I populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nemo Clinical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
- Pediatric Neurology, Catholic University of the Sacred Heart, Rome, Italy.
- Pediatric Neurology, Santobono-Pausilipon Children's Hospital, AORN, Naples, Italy.
- Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
- Unit of Muscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- The NEMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
ORCID-Profile: Giorgia Coratti, Adele D'Amico, Massimiliano Filosto, Michele Tosi
Förderung
- Biogen
- Novartis
- Roche Italia
- Ministero della Salute
- Piano Nazionale di Ripresa e Resilienza
- NextGenerationEU
Zitieren
APA
Pane, M., Coratti, G., Cutrì, C., Varone, A., Masson, R., D'Amico, A., Sansone, V., Messina, S., Ricci, F., Ticci, C., Bruno, C., Agosto, C., Benedetti, F., Pini, A., Siliquini, S., Filosto, M., Zambon, A., Bitetti, I., Manna, M. R., …, & ITASMAC working group (2026). Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70356
Vancouver
Pane M, Coratti G, Cutrì C, Varone A, Masson R, D'Amico A, et al. Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70356
BibTeX
@article{Pane2026,
author = {Pane, Marika and Coratti, Giorgia and Cutrì, Chiara and Varone, Antonio and Masson, Riccardo and D'Amico, Adele and Sansone, Valeria and Messina, Sonia and Ricci, Federica and Ticci, Chiara and Bruno, Claudio and Agosto, Caterina and Benedetti, Francesca and Pini, Antonella and Siliquini, Sabrina and Filosto, Massimiliano and Zambon, Alberto and Bitetti, Ilaria and Manna, Maria Rosaria and Dosi, Claudia and Zanin, Riccardo and Parravicini, Stefano and De Sanctis, Roberto and Stanca, Giulia and Catteruccia, Michela and Tosi, Michele and Mizzoni, Irene and Albamonte, Emilio and Franchino, Valentina and Sframeli, Maria and Cavallina, Ilaria and Procopio, Elena and Sacchini, Michele and Morando, Simone and Brolatti, Noemi and Trucco, Federica and Scarpini, Gaia and Briganti, Elena and Berti, Beatrice and Palermo, Concetta and Leone, Daniela and Previtali, Stefano C and Mercuri, Eugenio and ITASMAC working group, ITASMAC working group},
title = {Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
doi = {10.1002/acn3.70356}
}
EUVIMED